Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 18/20 | 0.56 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.49 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13738809 | 0.85 | PDE5A (0.55) | PDE5AGUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL15796081 | 0.83 | PDE5A (0.56) | PDE5AGUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL2453628 | 0.83 | GUCY1A1 (0.58) | PDE5AGUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL15796066 | 0.83 | GUCY1A1 (0.52) | PDE5AGUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL17619363 | 0.78 | PDE5A (0.54) | PDE5AGUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL2451684 | 0.77 | GUCY1A1 (0.51) | PDE5AGUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL9913994 | 0.75 | PDE5A (0.77) | PDE5A | |
| SCHEMBL17619288 | 0.72 | PDE5A (0.68) | PDE5A | |
| SCHEMBL15693415 | 0.72 | GUCY1A1 (0.62) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL17619345 | 0.72 | PDE5A (0.60) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2705037-B1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2705037-B1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-06-22 | — | — | EP | disclosed |
| US-20140171434-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND THE USE THEREOF | BAYER PHARMA AKTIENGESSELLSCHAFT (DE) | 2014-06-19 | — | — | US | disclosed |
| US-20140171434-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND THE USE THEREOF | BAYER PHARMA AKTIENGESSELLSCHAFT (DE) | 2014-06-19 | — | — | US | disclosed |
| US-20140171434-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND THE USE THEREOF | BAYER PHARMA AKTIENGESSELLSCHAFT (DE) | 2014-06-19 | — | — | US | disclosed |
| EP-2705037-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND THE USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012152629-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171434-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND THE USE THEREOF | TPMT, PPIP5K2, DPP4 | PDE5A 484/4885GUCY1A1 1969/4885GUCY1B1 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.